HRP20040156B1 - Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation - Google Patents

Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation

Info

Publication number
HRP20040156B1
HRP20040156B1 HR20040156A HRP20040156A HRP20040156B1 HR P20040156 B1 HRP20040156 B1 HR P20040156B1 HR 20040156 A HR20040156 A HR 20040156A HR P20040156 A HRP20040156 A HR P20040156A HR P20040156 B1 HRP20040156 B1 HR P20040156B1
Authority
HR
Croatia
Prior art keywords
preparation
lercanidipine hydrochloride
polymorphic forms
novel crystalline
crystalline polymorphic
Prior art date
Application number
HR20040156A
Other languages
English (en)
Croatian (hr)
Inventor
Bonifacio Fausto
Campana Francesco
De Iasi Gianluca
Leonardi Amedeo
Original Assignee
Recordati Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11448245&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20040156(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ireland Limited filed Critical Recordati Ireland Limited
Publication of HRP20040156A2 publication Critical patent/HRP20040156A2/hr
Publication of HRP20040156B1 publication Critical patent/HRP20040156B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
HR20040156A 2001-08-06 2002-08-05 Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation HRP20040156B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001726A ITMI20011726A1 (it) 2001-08-06 2001-08-06 Forme polimorfe della lercanidipina cloridrato
PCT/EP2002/008699 WO2003014084A1 (en) 2001-08-06 2002-08-05 Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation

Publications (2)

Publication Number Publication Date
HRP20040156A2 HRP20040156A2 (en) 2004-08-31
HRP20040156B1 true HRP20040156B1 (en) 2012-03-31

Family

ID=11448245

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040156A HRP20040156B1 (en) 2001-08-06 2002-08-05 Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation

Country Status (35)

Country Link
EP (4) EP2157083B1 (sr)
JP (1) JP2005504045A (sr)
KR (3) KR100626819B1 (sr)
CN (2) CN101475524B (sr)
AP (1) AP1766A (sr)
AR (1) AR037139A1 (sr)
AT (2) ATE307114T1 (sr)
AU (1) AU2002327924C1 (sr)
BR (1) BR0211739A (sr)
CY (2) CY1109711T1 (sr)
DE (2) DE60234961D1 (sr)
DK (3) DK1600441T3 (sr)
EA (1) EA005673B1 (sr)
EC (1) ECSP044973A (sr)
ES (3) ES2212759T3 (sr)
HR (1) HRP20040156B1 (sr)
HU (1) HU229563B1 (sr)
IL (3) IL153917A (sr)
IT (1) ITMI20011726A1 (sr)
MA (1) MA27133A1 (sr)
ME (2) ME01525B (sr)
MX (1) MXPA04001069A (sr)
NO (2) NO325541B1 (sr)
NZ (2) NZ541341A (sr)
OA (1) OA12648A (sr)
PE (1) PE20030328A1 (sr)
PL (1) PL216066B1 (sr)
PT (2) PT2157083E (sr)
RS (1) RS52161B (sr)
SI (3) SI1432683T1 (sr)
TN (1) TNSN04024A1 (sr)
UA (1) UA82988C2 (sr)
UY (1) UY27410A1 (sr)
WO (1) WO2003014084A1 (sr)
ZA (1) ZA200401806B (sr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
AR043395A1 (es) * 2003-02-28 2005-07-27 Recordati Ireland Ltd Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii
KR20060125824A (ko) * 2003-12-01 2006-12-06 라이프사이클 파마 에이/에스 레르카니디핀을 포함한 약학적 조성물
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
EP1940790B1 (en) 2005-09-16 2015-09-02 Glenmark Pharmaceuticals Limited Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
KR100821165B1 (ko) * 2006-03-10 2008-04-14 동우신테크 주식회사 레르카니디핀 염산염의 제조 방법
JP2010514753A (ja) * 2006-12-29 2010-05-06 ドンウ シンテック カンパニー リミテッド レルカニジピン塩酸塩の製造方法
US20100104649A1 (en) * 2007-03-05 2010-04-29 Actavis Group Ptc Ehf Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate
EA027787B1 (ru) 2010-06-23 2017-09-29 Крка, Товарна Здравил, Д.Д., Ново Место Пероральные лекарственные формы, содержащие лерканидипин и эналаприл и их фармацевтически приемлемые соли
EP2444394A1 (en) 2010-10-21 2012-04-25 Alembic Pharmaceuticals Limited Process for the preparation of amorphous form of lercanidipine HCI
WO2012085249A2 (en) 2010-12-24 2012-06-28 Krka, D.D., Novo Mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts
US20140031557A1 (en) * 2011-04-18 2014-01-30 Hefeibeinie Medical Technology Company, Ltd. Method for purification of calcium channel blockers of dihydorpyridine type and preparation of nanoparticles thereof
CN102531999B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 无定形盐酸乐卡地平及其制备方法
CN102558032B (zh) * 2011-12-16 2014-02-26 华润赛科药业有限责任公司 一种无定形盐酸乐卡地平及其制备方法
CN102584682A (zh) * 2011-12-31 2012-07-18 苏州二叶制药有限公司 盐酸乐卡地平的制备方法
CN103497075B (zh) * 2013-09-25 2016-03-23 山西北化关铝化工有限公司 水悬浮延期药造型粉
CN109232389B (zh) * 2018-05-15 2021-10-08 迪嘉药业集团有限公司 一种小粒度硝苯地平的结晶制备方法
CN115353485B (zh) * 2022-07-26 2024-04-19 山西双雁药业有限公司 从硝苯地平母液中回收硝苯地平的方法及应用
CN115671066B (zh) * 2022-11-21 2024-07-02 安徽宏业药业有限公司 一种盐酸乐卡地平片及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705797A (en) * 1984-02-14 1987-11-10 Recordati S.A., Chemical And Pharmaceutical Company N-(3,3-diphenylpropyl) aminoethyl esters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid, compositions and use
WO1996035668A1 (en) * 1995-05-12 1996-11-14 Recordati S.A., Chemical And Pharmaceutical Company A process for the preparation of lercanidipine hydrochloride
WO1997003669A1 (en) * 1995-07-14 1997-02-06 Recordati S.A., Chemical And Pharmaceutical Company Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596139A (en) * 1897-12-28 Process of generating acetylene gas
PL365238A1 (en) 2000-02-16 2004-12-27 Neurogen Corporation Substituted arylpyrazines
ITMI20011726A1 (it) 2001-08-06 2003-02-06 Recordati Ind Chimica E Farma Forme polimorfe della lercanidipina cloridrato
US20040198789A1 (en) 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705797A (en) * 1984-02-14 1987-11-10 Recordati S.A., Chemical And Pharmaceutical Company N-(3,3-diphenylpropyl) aminoethyl esters of 1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylic acid, compositions and use
WO1996035668A1 (en) * 1995-05-12 1996-11-14 Recordati S.A., Chemical And Pharmaceutical Company A process for the preparation of lercanidipine hydrochloride
US5696139A (en) * 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
WO1997003669A1 (en) * 1995-07-14 1997-02-06 Recordati S.A., Chemical And Pharmaceutical Company Use of 1,4-dihydropyridine derivatives in the prevention and therapy of atherosclerotic degradation of arterial walls

Also Published As

Publication number Publication date
MXPA04001069A (es) 2005-02-17
PL216066B1 (pl) 2014-02-28
DK2157083T3 (en) 2015-11-02
RS11304A (sr) 2007-02-05
UA82988C2 (uk) 2008-06-10
EP2157083B1 (en) 2015-09-30
SI1432683T1 (sl) 2006-04-30
EA005673B1 (ru) 2005-04-28
KR20050043992A (ko) 2005-05-11
ATE307114T1 (de) 2005-11-15
IL153917A (en) 2005-11-20
AU2002327924C1 (en) 2009-12-10
ITMI20011726A1 (it) 2003-02-06
PT1600441E (pt) 2010-01-20
EP1600441A3 (en) 2005-12-07
ME01525B (me) 2011-02-10
CY1109711T1 (el) 2014-08-13
SI1600441T1 (sl) 2010-02-26
DE60234961D1 (de) 2010-02-11
DK1600441T3 (da) 2010-02-08
JP2005504045A (ja) 2005-02-10
WO2003014084A1 (en) 2003-02-20
KR100626819B1 (ko) 2006-09-20
IL164648A (en) 2007-02-11
EP1432683B1 (en) 2005-10-19
NO335651B1 (no) 2015-01-19
PT2157083E (pt) 2016-01-22
EP2036890A1 (en) 2009-03-18
CN100448847C (zh) 2009-01-07
HUP0401163A3 (en) 2009-04-28
EP2157083A2 (en) 2010-02-24
IL164648A0 (en) 2005-12-18
ES2555213T3 (es) 2015-12-29
NZ541341A (en) 2007-02-23
PE20030328A1 (es) 2003-05-09
CN101475524B (zh) 2012-08-29
MEP2908A (en) 2010-10-10
EP1432683B9 (en) 2006-01-18
CN1538957A (zh) 2004-10-20
RS52161B (sr) 2012-08-31
ATE453624T1 (de) 2010-01-15
AR037139A1 (es) 2004-10-27
EA200400280A1 (ru) 2004-08-26
UY27410A1 (es) 2003-03-31
NZ531558A (en) 2005-12-23
DK1432683T3 (da) 2006-03-06
KR100667687B1 (ko) 2007-01-12
NO20040266L (no) 2004-03-24
CY1117051T1 (el) 2017-04-05
EP1600441B1 (en) 2009-12-30
HK1067123A1 (en) 2005-04-01
DE60206787T2 (de) 2006-07-13
ES2212759T3 (es) 2006-04-16
PL369522A1 (en) 2005-05-02
HK1140487A1 (en) 2010-10-15
HK1086263A1 (en) 2006-09-15
EP1600441A2 (en) 2005-11-30
TNSN04024A1 (en) 2006-06-01
KR20040030903A (ko) 2004-04-09
ZA200401806B (en) 2005-06-29
SI2157083T1 (sl) 2016-01-29
EP2157083A3 (en) 2010-03-24
AP1766A (en) 2007-08-10
CN101475524A (zh) 2009-07-08
AP2004002989A0 (en) 2004-03-31
NO325541B1 (no) 2008-06-16
ES2212759T1 (es) 2004-08-01
IL153917A0 (en) 2003-07-31
AU2002327924B2 (en) 2008-04-24
NO20082330L (no) 2004-03-24
HU229563B1 (en) 2014-02-28
ITMI20011726A0 (it) 2001-08-06
ECSP044973A (es) 2004-06-28
KR20050111799A (ko) 2005-11-28
ES2334678T3 (es) 2010-03-15
HUP0401163A2 (hu) 2004-09-28
DE60206787D1 (de) 2006-03-02
EP1432683A1 (en) 2004-06-30
OA12648A (en) 2006-06-16
BR0211739A (pt) 2004-09-28
MA27133A1 (fr) 2005-01-03
HRP20040156A2 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
HRP20040156B1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
AP1830A (en) Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same.
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
DE69705829D1 (de) Meta-substituierte phenylsulphonamidderivate
WO2002085925A3 (en) Melanocortin receptor ligands
HRP20090195T1 (hr) Inhibitori mitotičkih kinezina
DK1253153T3 (da) Fremgangsmåde til fremstilling af 4"-substituerede-9-deoxo-9a-aza-9a-homoerythromycin-A-derivater
NO329883B1 (no) Fremgangsmate for fremstilling av prostaglandiner og analoger derav og av mellomforbindelser, og forbindelser fremstilt derved
WO2004046112A3 (en) 3-amino-piperidine derivatives and processes for their preparation
NO20040794L (no) (-)-1-(3,4-Diklorfenyl)-3-azabicyklo[3.1.0]heksan, forbindelser derav og anvendelser som en dopamin-gjenopptaks-inhibitor.
NO20022558L (no) 4-karboksyamino-2-etyl-1,2,3,4-tetrahydrokinolinkrystall som CETP inhibitor
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
WO2004043920A8 (en) Polymorphs of bicifadine hydrochloride
DK0623121T3 (da) Fremstilling af N-acetylneuraminsyrederivater
BR0209901A (pt) Processos para a sìntese de derivados de 2,3-dihidro-1,4-dioxino-[2,3-f] quinolina
CA2337452A1 (en) Process for the preparation of 4,5-diamino shikimic acid derivatives
PL361850A1 (en) Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
JO2302B1 (en) The process of preparing derivatives of 5.4-diamino shemic acid
DK1335922T3 (da) Fremgangsmåde til fremstilling af 4'-demethyl-4'-O-substituerede 1-deoxypodophyllotoxinderivater og geometriske isomerer deraf og anticancersammensætninger, der indeholder samme
DK1414961T3 (da) Nye oligoribonukleotid-derivater til målrettet inhibition af genekspression
WO2003005970A3 (en) Carvedilol polymorph
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK1408035T3 (da) Fremgangsmåde til fremstilling af derivater af 1,5-diaryl-3-trifluormethyl-delta2-pyrazoliner, der er racemiske og enantiomert rene
AU2001282744A1 (en) Process for asymmetric synthesis of substituted 1,4-dihydropyridines
WO2003045909A3 (en) Methods and intermediates for the synthesis of azepines

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20190715

Year of fee payment: 18

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200727

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20210803

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20220805